Vol. 7, Issue 1, Part F (2025)

Red Blood Cell (RBC) camouflage nanoparticles represent a novel and promising strategy in drug delivery systems, leveraging the natural biocompatibility and long circulation time of RBC membranes. By coating nanoparticles with RBC-derived membranes, these systems can evade immune detection, thereby enhancing systemic stability and prolonging blood retention time. This biomimetic approach significantly reduces clearance by the mononuclear phagocyte system and minimizes potential immunogenicity. Such nanoparticles can be engineered to carry a variety of therapeutic agents, including chemotherapeutics, proteins, and nucleic acids, and can be further functionalized for targeted delivery to specific tissues or disease sites. The integration of RBC membranes with advanced nanocarriers offers a synergistic platform that combines the advantages of natural cell membranes and synthetic nanoparticle cores, enhancing therapeutic efficacy while reducing side effects. RBC camouflage nanoparticles thus hold great potential in improving the clinical outcomes of various treatments, particularly in cancer therapy and chronic disease management.